News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,332 Results
Type
Article (13872)
Company Profile (295)
Press Release (246165)
Section
Business (79324)
Career Advice (150)
Deals (13180)
Drug Delivery (32)
Drug Development (50285)
Employer Resources (31)
FDA (5670)
Job Trends (5113)
News (144062)
Policy (10014)
Tag
Academia (901)
Alliances (21469)
Alzheimer's disease (736)
Approvals (5645)
Artificial intelligence (63)
Bankruptcy (97)
Best Places to Work (4498)
Biotechnology (242)
Breast cancer (66)
Cancer (699)
Cardiovascular disease (62)
Career advice (131)
CAR-T (57)
Cell therapy (178)
Clinical research (39815)
Collaboration (239)
Compensation (99)
COVID-19 (1002)
C-suite (68)
Cystic fibrosis (66)
Data (798)
Diabetes (73)
Diagnostics (1201)
Earnings (28977)
Events (46852)
Executive appointments (193)
FDA (5964)
Funding (252)
Gene editing (55)
Gene therapy (148)
GLP-1 (301)
Government (1063)
Healthcare (6532)
Infectious disease (1037)
Inflammatory bowel disease (94)
IPO (7182)
Job creations (859)
Job search strategy (126)
Layoffs (184)
Legal (1373)
Lung cancer (111)
Manufacturing (74)
Medical device (2552)
Medtech (2553)
Mergers & acquisitions (6102)
Metabolic disorders (225)
Neuroscience (946)
NextGen Class of 2024 (1998)
Non-profit (846)
Northern California (951)
Obesity (124)
Opinion (91)
Parkinson's disease (61)
Patents (52)
People (24985)
Pharmaceutical (50)
Phase I (14009)
Phase II (18522)
Phase III (11736)
Pipeline (324)
Postmarket research (846)
Preclinical (5929)
Radiopharmaceuticals (205)
Rare diseases (169)
Real estate (1409)
Regulatory (8206)
Research institute (930)
Southern California (868)
Startups (1964)
United States (7654)
Vaccines (160)
Weight loss (76)
Date
Today (24)
Last 7 days (419)
Last 30 days (2197)
Last 365 days (20738)
2024 (19058)
2023 (22412)
2022 (26822)
2021 (27806)
2020 (23358)
2019 (16224)
2018 (11739)
2017 (13746)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16832)
Australia (2839)
California (2158)
Canada (718)
China (166)
Colorado (82)
Connecticut (86)
Europe (36250)
Florida (232)
Georgia (62)
Illinois (126)
Indiana (54)
Kansas (55)
Maryland (300)
Massachusetts (1712)
Michigan (48)
Minnesota (94)
New Jersey (549)
New York (615)
North Carolina (399)
Northern California (951)
Ohio (79)
Pennsylvania (429)
South America (207)
Southern California (868)
Texas (232)
Washington State (221)
260,332 Results for "proqr therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massachusetts.
June 18, 2024
·
5 min read
Press Releases
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
October 7, 2024
·
5 min read
Press Releases
ProQR Announces Third Quarter 2024 Operating and Financial Results
November 7, 2024
·
16 min read
Business
ProQR Announces First Quarter 2024 Operating and Financial Results
ProQR Therapeutics NV. reported its financial and operating results for the first quarter ended March 31, 2024, and provided a business update.
May 9, 2024
·
17 min read
Press Releases
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
October 23, 2024
·
4 min read
Press Releases
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
October 28, 2024
·
3 min read
Policy
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
ProQR Therapeutics N.V. today announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer™.
April 19, 2024
·
5 min read
Business
ProQR Announces Year End 2023 Operating and Financial Results
ProQR Therapeutics NV. reported its financial and operating results for the year ended December 31, 2023, and provided a business update.
March 13, 2024
·
13 min read
Genetown
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR) today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing technology platform, including the first preclinical data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.
April 22, 2024
·
5 min read
Business
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
ProQR Therapeutics NV. announced the Annual General Meeting of Shareholders will take place on Wednesday, May 22, 2024 at 1630 CET at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands.
April 23, 2024
·
7 min read
1 of 26,034
Next
